Literature DB >> 31506247

A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials.

Chengjie Xiong1, Jingqin Luo2, Folasade Agboola3, Yan Li4, Marilyn Albert5, Sterling C Johnson6, Rebecca L Koscik7, Colin L Masters8, Anja Soldan5, Victor L Villemagne9, Qiao-Xin Li8, Eric M McDade10, Anne M Fagan11, Parinaz Massoumzadeh12, Tammie Benzinger12, Jason Hassenstab11, Randall J Bateman11, John C Morris13.   

Abstract

INTRODUCTION: Large longitudinal biomarkers database focusing on middle age is needed for Alzheimer's disease (AD) prevention.
METHODS: Data for cerebrospinal fluid analytes, molecular imaging of cerebral fibrillar β-amyloid with positron emission tomography, magnetic resonance imaging-based brain structures, and clinical/cognitive outcomes were harmonized across eight AD biomarker studies. Statistical power was estimated.
RESULTS: The harmonized database included 7779 participants with clinical/cognitive data: 3542 were 18∼65 years at the baseline, 5865 had longitudinal cognitive data for a median of 4.7 years, 2473 participated in the cerebrospinal fluid studies (906 had longitudinal data), 2496 participated in the magnetic resonance imaging studies (1283 had longitudinal data), and 1498 participated in the positron emission tomography amyloid studies (849 had longitudinal data). The database provides adequate power for detecting early biomarker changes, and demonstrates the feasibility of AD prevention trials on middle-aged individuals. DISCUSSION: The harmonized database is an optimum resource to design AD prevention trials decades before symptomatic onset.
Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Amyloid imaging with positron emission tomography (PET) using the [(11)C] benzothiazole tracer; Biomarkers; Cerebrospinal fluid (CSF); Magnetic resonance imaging (MRI) volumetrics; Pittsburgh Compound-B (PIB); Preclinical stages; Prevention trials

Mesh:

Substances:

Year:  2019        PMID: 31506247      PMCID: PMC6874758          DOI: 10.1016/j.jalz.2019.06.4955

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  34 in total

1.  Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

Authors:  J L Price; J C Morris
Journal:  Ann Neurol       Date:  1999-03       Impact factor: 10.422

2.  Role of family history for Alzheimer biomarker abnormalities in the adult children study.

Authors:  Chengjie Xiong; Catherine M Roe; Virginia Buckles; Anne Fagan; David Holtzman; David Balota; Janet Duchek; Martha Storandt; Mark Mintun; Elizabeth Grant; Abraham Z Snyder; Denise Head; Tammie L S Benzinger; Joseph Mettenburg; John Csernansky; John C Morris
Journal:  Arch Neurol       Date:  2011-10

3.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

4.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

5.  Increased florbetapir binding in the temporal neocortex from age 20 to 60 years.

Authors:  Julie Gonneaud; Eider M Arenaza-Urquijo; Florence Mézenge; Brigitte Landeau; Malo Gaubert; Alexandre Bejanin; Robin de Flores; Miranka Wirth; Clémence Tomadesso; Géraldine Poisnel; Ahmed Abbas; Béatrice Desgranges; Gaël Chételat
Journal:  Neurology       Date:  2017-11-17       Impact factor: 9.910

6.  Amyloid burden and neural function in people at risk for Alzheimer's Disease.

Authors:  Sterling C Johnson; Bradley T Christian; Ozioma C Okonkwo; Jennifer M Oh; Sandra Harding; Guofan Xu; Ansel T Hillmer; Dustin W Wooten; Dhanabalan Murali; Todd E Barnhart; Lance T Hall; Annie M Racine; William E Klunk; Chester A Mathis; Barbara B Bendlin; Catherine L Gallagher; Cynthia M Carlsson; Howard A Rowley; Bruce P Hermann; N Maritza Dowling; Sanjay Asthana; Mark A Sager
Journal:  Neurobiol Aging       Date:  2013-10-23       Impact factor: 4.673

7.  Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid.

Authors:  Tobias Bittner; Henrik Zetterberg; Charlotte E Teunissen; Richard E Ostlund; Michael Militello; Ulf Andreasson; Isabelle Hubeek; David Gibson; David C Chu; Udo Eichenlaub; Peter Heiss; Uwe Kobold; Andreas Leinenbach; Kairat Madin; Ekaterina Manuilova; Christina Rabe; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2015-11-10       Impact factor: 21.566

8.  CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease.

Authors:  Barbara B Bendlin; Cynthia M Carlsson; Sterling C Johnson; Henrik Zetterberg; Kaj Blennow; Auriel A Willette; Ozioma C Okonkwo; Aparna Sodhi; Michele L Ries; Alex C Birdsill; Andrew L Alexander; Howard A Rowley; Luigi Puglielli; Sanjay Asthana; Mark A Sager
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

Review 9.  The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions.

Authors:  Sterling C Johnson; Rebecca L Koscik; Erin M Jonaitis; Lindsay R Clark; Kimberly D Mueller; Sara E Berman; Barbara B Bendlin; Corinne D Engelman; Ozioma C Okonkwo; Kirk J Hogan; Sanjay Asthana; Cynthia M Carlsson; Bruce P Hermann; Mark A Sager
Journal:  Alzheimers Dement (Amst)       Date:  2017-12-08

10.  STRengthening analytical thinking for observational studies: the STRATOS initiative.

Authors:  Willi Sauerbrei; Michal Abrahamowicz; Douglas G Altman; Saskia le Cessie; James Carpenter
Journal:  Stat Med       Date:  2014-07-30       Impact factor: 2.373

View more
  4 in total

1.  Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults.

Authors:  Chengjie Xiong; Jingqin Luo; Suzanne E Schindler; Anne M Fagan; Tammie Benzinger; Jason Hassenstab; Joyce E Balls-Berry; Folasade Agboola; Elizabeth Grant; Krista L Moulder; John C Morris
Journal:  Alzheimers Dement       Date:  2022-02-25       Impact factor: 16.655

2.  A family of estimators to diagnostic accuracy when candidate tests are subject to detection limits-Application to diagnosing early stage Alzheimer disease.

Authors:  Chengjie Xiong; Jingqin Luo; Folasade Agboola; Elizabeth Grant; John C Morris
Journal:  Stat Methods Med Res       Date:  2022-01-19       Impact factor: 2.494

3.  Association of accelerated long-term forgetting and senescence-related blood-borne factors in asymptomatic individuals from families with autosomal dominant Alzheimer's disease.

Authors:  Jianwei Yang; Chaojun Kong; Longfei Jia; Tingting Li; Meina Quan; Yan Li; Diyang Lyu; Fangyu Li; Hongmei Jin; Ying Li; Qigeng Wang; Jianping Jia
Journal:  Alzheimers Res Ther       Date:  2021-05-27       Impact factor: 6.982

4.  Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study.

Authors:  Jingqin Luo; Folasade Agboola; Elizabeth Grant; Colin L Masters; Marilyn S Albert; Sterling C Johnson; Eric M McDade; Jonathan Vöglein; Anne M Fagan; Tammie Benzinger; Parinaz Massoumzadeh; Jason Hassenstab; Randall J Bateman; John C Morris; Richard J Perrin; Jasmeer Chhatwal; Mathias Jucker; Bernardino Ghetti; Carlos Cruchaga; Neill R Graff-Radford; Peter R Schofield; Hiroshi Mori; Chengjie Xiong
Journal:  Neurology       Date:  2020-09-01       Impact factor: 11.800

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.